Candel Therapeutics, Inc.
NASDAQ:CADLBiotechnology
+$0.05 today
- Market cap
- $417.33M
- Beta
- -0.48
- P/E (TTM)
- -9.2
- EPS (TTM)
- -$0.87
Volume 1.39M
Average 1.82M
CADL Account Payables
Amounts the company owes suppliers for goods and services received.
Candel Therapeutics, Inc.NASDAQ: CADL
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables rises 299.5% from a year ago
Account payables stood at $3.04M at the end of Q1 FY2026, up 299.5% from a year earlier and up 168.9% from the prior quarter. Over 3 fiscal years it compounded at +43.8% a year.
Context
- Account payables amounted to 1.5% of total assets at the end of Q1 FY2026, up 0.7 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps rising in the next quarterly balance sheet after a +299.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 1.13M USD
- Year-over-year change
- +376.4%
- 4-year CAGR
- -8.2%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.13M | +376.4% |
| FY2024 | 2024-12-31 | 237K | -43.8% |
| FY2023 | 2023-12-31 | 422K | +11.1% |
| FY2022 | 2022-12-31 | 380K | -76.1% |
| FY2021 | 2021-12-31 | 1.59M | — |
Account Payables vs competitors
How CADL compares with its peers on the latest reported figures
- CADL's Mar 2026 account payables of $3.04M is the 8th highest of the 10 companies compared; the peer median is $4.73M.
- Its year-over-year change of +299.5% is the highest of 9, against a peer median of -14.7%.
- Account payables amounts to 1.5% of total assets for CADL, versus a peer median of 2.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $21.65M | -30.7% | -5.9% | 2.2% | |
| Mar 2026 | $10.84M | +7.9% | +56.2% | 2.3% | |
| Mar 2026 | $8.17M | +35.5% | -7.7% | 4.2% | |
GNLXGenelux Corporation | Mar 2026 | $6.1M | -8.9% | -13.7% | 18.8% |
| Mar 2026 | $4.73M | -17.6% | +236.3% | 4.9% | |
| Mar 2026 | $4.29M | -35.2% | -0.8% | 2.0% | |
| Mar 2026 | $3.15M | -11.8% | -4.3% | 1.0% | |
| Mar 2026 | $3.04M | +299.5% | +43.8% | 1.5% | |
| Mar 2026 | $2.9M | -43.9% | +42.6% | 0.7% | |
NBPNovaBridge Biosciences | Dec 2025 | $0 | — | — | 0.0% |
| Peer median (excluding CADL) | $4.73M | -14.7% | -2.6% | 2.2% | |
Competitors are the stored peer set for CADL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 82.64M | 70.06M | 35.41M | 102.65M | 119.73M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 2.3M | 1.89M | 1.38M | 0 | 0 |
| Total Current Assets | 84.95M | 71.95M | 36.8M | 103.8M | 119.73M |
| Property, Plant & Equipment (Net) | 3.84M | 5.48M | 4.02M | 2.73M | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 424K | 266K | 0 | 0 | 416K |
| Tax Assets | 0 | 828K | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 382K | 329K | 5.05M |
| Total Non-current Assets | 4.26M | 6.57M | 4.4M | 3.06M | 5.46M |
| Total Assets | 89.21M | 78.52M | 41.2M | 106.87M | 125.2M |
| Account Payables | 1.59M | 380K | 422K | 237K | 1.13M |
| Short-term Debt | 0 | 464K | 8.89M | 9.9M | 445K |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 1.68M | 2.12M | 2.34M | 22.11M | 7.42M |
| Total Current Liabilities | 5.36M | 5.62M | 14.18M | 37.53M | 9M |
| Long-term Debt | 560K | 20.85M | 12.38M | 2.6M | 1.46M |
| Deferred Tax Liabilities | 0 | 828K | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 144K | 0 | 0 | 0 |
| Other Non-current Liabilities | 19.15M | 1.88M | 916K | 0 | 62.82M |
| Total Non-current Liabilities | 19.71M | 25.19M | 14.27M | 3.01M | 64.28M |
| Total Liabilities | 25.07M | 30.81M | 28.46M | 40.54M | 73.27M |
| Common Stock | 286K | 290K | 290K | 469K | 550K |
| Retained Earnings | (80.3M) | (99.09M) | (137.03M) | (192.21M) | (230.39M) |
| Accumulated OCI | (89.21M) | 0 | 0 | (0) | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 64.14M | 47.71M | 12.75M | 66.33M | 51.92M |
| Total Debt | 560K | 22.8M | 22.76M | 13.47M | 1.9M |
| Net Debt | (82.08M) | (47.26M) | (12.65M) | (89.18M) | (117.83M) |
Candel Therapeutics, Inc.
NASDAQ:CADL
Intrinsic Alpha fair value
Locked
Current Price
$5.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.